New antibiotic strategy shows promise against MRSA in cystic fibrosis
NCT ID NCT03489629
First seen Feb 20, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This phase 2 trial tested whether giving two rounds of antibiotics (TMP/SMX or minocycline) early and repeatedly could clear MRSA infections in people with cystic fibrosis. The study enrolled 37 participants aged 2 to 45. The main goal was to see if this approach led to negative MRSA cultures after treatment, compared to a historical control group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
N.C. Memorial Hospital and N.C. Children's Hospital
Chapel Hill, North Carolina, 27599, United States
-
National Jewish Health
Denver, Colorado, 80206, United States
-
St. Louis Children's Hospital
St Louis, Missouri, 63110, United States
-
Texas Children's Hospital, Baylor College of Medicine
Houston, Texas, 77030, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Washington Medical Center and Seattle Children's
Seattle, Washington, 98195, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trimethoprim Sulfamethoxazole (TMP/SMX) or Minocycline
What this could lead to
If successful, this approach could help clear MRSA infections early in people with cystic fibrosis, potentially reducing lung damage and hospitalizations.
What could go wrong
This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. Antibiotic resistance and side effects are possible risks.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.